FI973750A0 - Framställnig och kristallina former av 2-metyltienobensodiazepin - Google Patents

Framställnig och kristallina former av 2-metyltienobensodiazepin

Info

Publication number
FI973750A0
FI973750A0 FI973750A FI973750A FI973750A0 FI 973750 A0 FI973750 A0 FI 973750A0 FI 973750 A FI973750 A FI 973750A FI 973750 A FI973750 A FI 973750A FI 973750 A0 FI973750 A0 FI 973750A0
Authority
FI
Finland
Prior art keywords
methylthienobenzodiazepine
preparation
crystalline forms
crystalline
forms
Prior art date
Application number
FI973750A
Other languages
English (en)
Finnish (fi)
Other versions
FI973750A (sv
Inventor
Charles Arthur Bunnell
Barry Arnold Hendriksen
Original Assignee
Lilly Co Eli
Lilly Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23621056&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI973750(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli, Lilly Industries Ltd filed Critical Lilly Co Eli
Publication of FI973750A publication Critical patent/FI973750A/sv
Publication of FI973750A0 publication Critical patent/FI973750A0/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
FI973750A 1995-03-24 1997-09-22 Framställnig och kristallina former av 2-metyltienobensodiazepin FI973750A0 (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40956695A 1995-03-24 1995-03-24
PCT/US1996/003917 WO1996030375A1 (en) 1995-03-24 1996-03-22 Process and crystal forms of 2-methyl-thieno-benzodiazepine

Publications (2)

Publication Number Publication Date
FI973750A FI973750A (sv) 1997-09-22
FI973750A0 true FI973750A0 (sv) 1997-09-22

Family

ID=23621056

Family Applications (1)

Application Number Title Priority Date Filing Date
FI973750A FI973750A0 (sv) 1995-03-24 1997-09-22 Framställnig och kristallina former av 2-metyltienobensodiazepin

Country Status (49)

Country Link
US (1) US5736541A (sv)
EP (3) EP0733635B1 (sv)
JP (1) JPH11502535A (sv)
KR (1) KR100399688B1 (sv)
CN (1) CN1065536C (sv)
AP (1) AP828A (sv)
AR (2) AR010448A1 (sv)
AT (4) AT406771B (sv)
AU (1) AU706471B2 (sv)
BG (1) BG62619B1 (sv)
BR (1) BR9607790A (sv)
CA (1) CA2214005C (sv)
CH (1) CH690579A5 (sv)
CO (1) CO4650278A1 (sv)
CZ (1) CZ292688B6 (sv)
DE (4) DE19681286T1 (sv)
DK (4) DK0733635T3 (sv)
EA (1) EA000149B1 (sv)
EE (1) EE03489B1 (sv)
EG (1) EG23659A (sv)
ES (3) ES2208220T3 (sv)
FI (1) FI973750A0 (sv)
GB (1) GB2313835B (sv)
HK (1) HK1013988A1 (sv)
HU (1) HU224989B1 (sv)
IL (1) IL117610A (sv)
IS (1) IS1896B (sv)
LT (1) LT4349B (sv)
LU (1) LU90096B1 (sv)
LV (1) LV12018B (sv)
MY (1) MY114701A (sv)
NO (1) NO314663B1 (sv)
NZ (1) NZ306110A (sv)
OA (1) OA10510A (sv)
PA (1) PA8353701A1 (sv)
PE (1) PE44897A1 (sv)
PL (1) PL183723B1 (sv)
PT (3) PT1445259E (sv)
RO (1) RO118872B1 (sv)
SE (1) SE9703205D0 (sv)
SI (4) SI0733635T1 (sv)
SK (1) SK284143B6 (sv)
SV (1) SV1996000031A (sv)
TR (1) TR199701017T1 (sv)
TW (2) TW442488B (sv)
UA (1) UA44765C2 (sv)
WO (1) WO1996030375A1 (sv)
YU (1) YU49478B (sv)
ZA (2) ZA962342B (sv)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
CA2232559A1 (en) * 1995-09-29 1997-04-03 Charles Merritt Beasley Jr. Method for treating a tic disorder
UA57727C2 (uk) * 1996-03-11 2003-07-15 Елі Ліллі Енд Компані Спосіб лікування надмірної агресивності
EP0904083A4 (en) * 1996-03-25 2002-05-22 Lilly Co Eli METHOD FOR ANESTHESIA
PL329221A1 (en) * 1996-03-25 1999-03-15 Lilly Co Eli Method of relieving hemicrania pains
AU725556B2 (en) * 1996-03-25 2000-10-12 Eli Lilly And Company Method for treating pain
AU721338B2 (en) * 1996-03-25 2000-06-29 Eli Lilly And Company Method for treating pain
CZ299247B6 (cs) * 1996-09-23 2008-05-28 Eli Lilly And Company Olanzapin dihydrát D
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
DK1155696T3 (da) * 1997-04-15 2004-07-12 Lilly Co Eli Anvendelse af olanzapin til fremstillingen af et medikament til neurobeskyttelse
WO1998046596A1 (en) * 1997-04-15 1998-10-22 Eli Lilly And Company Method for providing neuro-protective effects
US20030022889A1 (en) * 1997-04-15 2003-01-30 Bymaster Franklin P. Method for providing neuro-protective effects
ZA982917B (en) * 1997-04-15 1999-10-06 Lilly Co Eli Method for treating cerebral focal stroke.
USRE43932E1 (en) 1997-07-18 2013-01-15 Novartis Ag Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
US6617321B2 (en) 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
NZ510208A (en) * 1998-09-30 2003-04-29 Lilly Co Eli Olanzapine (2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine) pamoate salt
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
US7022698B2 (en) 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
US6348458B1 (en) 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine
AU779452B2 (en) * 1999-12-28 2005-01-27 Cipla Limited New polymorphic forms of olanzapine
CA2420987A1 (en) * 2000-08-31 2002-03-07 Dr. Reddy's Laboratories Ltd. Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine
AU2001282913A1 (en) * 2000-09-08 2002-03-22 Eli Lilly And Company A method of treating weight gain associated with atypical antipsychotic use
US6740753B2 (en) 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
CA2464306A1 (en) * 2001-10-29 2003-05-08 Dr. Reddy's Laboratories Ltd. Olanzapine dihydrate-ii a process for its preparation and use thereof
CA2471341C (en) 2001-12-24 2012-01-24 Sun Pharmaceutical Industries Limited Crystalline form i of 2-methyl-4-(4-methyl-1-piperazinyl) 10h thieno [2,3-b][1,5]benzodiazepine
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
WO2004089313A2 (en) * 2003-04-01 2004-10-21 Transform Pharmaceuticals, Inc. Novel olanzapine forms and related methods of treatment
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
EP1494998A2 (en) 2002-03-01 2005-01-12 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
PL196814B1 (pl) * 2002-05-17 2008-02-29 Inst Farmaceutyczny Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
AU2003237305A1 (en) * 2002-05-31 2003-12-19 Geneva Pharmaceuticals, Inc. Process of preparation of olanzapine form i
CA2489984A1 (en) * 2002-06-21 2003-12-31 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
SI21270A (sl) * 2002-07-15 2004-02-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalne oblike olanzapina in postopki za njihovo pripravo
PL202856B1 (pl) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
US7323459B2 (en) 2002-12-24 2008-01-29 Teva Pharmaceutical Industries Ltd. Crystal forms, methods for their preparation and method for preparation of olanzapine
US8183290B2 (en) * 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
EP1507774A1 (en) * 2003-03-12 2005-02-23 Biogal Gyogyszergyar Rt. Processes for preparation of polymorphic forms of desloratadine
US20060135547A1 (en) * 2003-03-12 2006-06-22 Toth Zoltan G Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
GB0314149D0 (en) * 2003-06-18 2003-07-23 Generics Uk Ltd Novel amorphous forms
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
CA2546200A1 (en) * 2003-11-18 2005-06-02 3M Innovative Properties Company Olanzapine containing transdermal drug delivery compositions
US7425627B2 (en) * 2003-12-22 2008-09-16 Teva Pharmaceutical Industries Ltd. Methods of synthesizing olanzapine
US20050272720A1 (en) * 2004-01-27 2005-12-08 Rolf Keltjens Process for making olanzapine Form I
DE602005027308D1 (de) 2004-01-27 2011-05-19 Synthon Bv Stabile salze von olanzapin
ES2253091B1 (es) 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
WO2006027800A1 (en) * 2004-09-06 2006-03-16 Shasun Chemicals And Drugs Limited A novel process for preparation of a pharmaceutically pure polymorphic form 1 of olanzapine
BRPI0518187A (pt) * 2004-11-16 2008-11-04 Elan Pharma Int Ltd formulações de olanzapina em nanopartìcula injetáveis
EP1838716B1 (en) 2005-01-05 2011-06-01 Eli Lilly And Company Olanzapine pamoate dihydrate
CZ200563A3 (cs) * 2005-02-02 2006-10-11 Zentiva, A. S. Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
US20100174066A1 (en) * 2005-03-21 2010-07-08 Venkataraman Sundaram Process for preparing crystalline form i of olanzapine
US20070021605A1 (en) * 2005-07-20 2007-01-25 Rolf Keltjens Process and composition for making olanzapine form i
WO2007020080A1 (en) * 2005-08-17 2007-02-22 Synthon B.V. A process for making olanzapine form i
GB0522474D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
HUP0501046A2 (en) * 2005-11-11 2007-08-28 Egis Gyogyszergyar Nyilvanosan Process for the preparation of olanzapine
US8721202B2 (en) 2005-12-08 2014-05-13 Ncr Corporation Two-sided thermal print switch
US8367580B2 (en) 2006-03-07 2013-02-05 Ncr Corporation Dual-sided thermal security features
US8222184B2 (en) 2006-03-07 2012-07-17 Ncr Corporation UV and thermal guard
ES2279715B1 (es) 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
US20070293479A1 (en) * 2006-05-18 2007-12-20 Osinga Niels J Olanzapine pharmaceutical composition
CL2007002807A1 (es) * 2006-09-29 2008-04-11 Synthon Bv Composicion farmaceutica en estado solido que comprende olanzapina o una sal farmaceuticamente aceptable de la misma y lactosa anhidra; tableta farmaceutica oral; procedimiento de preparacion de dicha tableta, util en el tratamiento de la esquizofren
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
PL381564A1 (pl) 2007-01-22 2008-08-04 Koźluk Tomasz Nobilus Ent Sposób wytwarzania zasadniczo czystej odmiany polimorficznej I olanzapiny
CA2591644A1 (en) * 2007-06-14 2008-12-14 Apotex Pharmachem Inc. Novel processes to form-i of olanzapine
US9056488B2 (en) 2007-07-12 2015-06-16 Ncr Corporation Two-side thermal printer
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
CN101735239B (zh) * 2008-11-06 2011-08-31 齐鲁制药有限公司 一种无水奥氮平晶型ii的制备方法
EP2292624A1 (en) 2009-07-20 2011-03-09 LEK Pharmaceuticals d.d. Process for the purification of olanzapine
HUE041981T2 (hu) 2010-08-23 2019-06-28 Alkermes Pharma Ireland Ltd Eljárások antipszichotikum által kiváltott súlygyarapodás kezelésére
CN102093386B (zh) * 2011-01-05 2016-06-01 浙江华海药业股份有限公司 一种制备奥兰扎平晶型ⅱ的方法
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
PL2888284T3 (pl) 2012-08-21 2023-02-27 Janssen Pharmaceutica Nv Przeciwciała przeciwko haptenom rysperydonu i ich zastosowanie
PT2887952T (pt) * 2012-08-21 2019-08-30 Janssen Pharmaceutica Nv Anticorpos para haptenos da olanzapina e suas utilizações
EP2888590B1 (en) 2012-08-21 2020-07-08 Janssen Pharmaceutica NV Antibodies to olanzapine and use thereof
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
CN103848847B (zh) * 2012-12-04 2018-02-06 广东东阳光药业有限公司 一种改进制备奥氮平及其晶型ii的方法
JP6008734B2 (ja) * 2012-12-20 2016-10-19 株式会社トクヤマ オランザピンｉｉ型結晶の製造方法
CN103145731B (zh) * 2013-02-26 2014-02-19 江苏豪森药业股份有限公司 奥氮平晶型及其制备方法和用途
WO2023139531A1 (en) 2022-01-20 2023-07-27 Teva Pharmaceuticals International Gmbh Olanzapine, compositions thereof and methods of use thereof
US20240238308A1 (en) 2023-01-10 2024-07-18 Medincell Sa Olanzapine compositions and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115568A (en) * 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
CA1097233A (en) 1977-07-20 1981-03-10 George K. E. Gregory Packages
US4237279A (en) * 1979-07-27 1980-12-02 Eli Lilly And Company Crystalline 3-hydroxycephalosporin solvates
IE53696B1 (en) 1981-12-02 1989-01-18 Wyeth John & Brother Ltd Solid shaped articles
US5039540A (en) 1989-08-14 1991-08-13 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5079018A (en) 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
PT582368E (pt) * 1992-05-29 2001-05-31 Lilly Co Eli Derivados de tienobenzodiazepina para o tratamento de doencas de cns
US5439888A (en) * 1994-03-04 1995-08-08 Eli Lilly And Company Antithrombotic agents
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine

Also Published As

Publication number Publication date
SI1445259T1 (sl) 2006-10-31
FI973750A (sv) 1997-09-22
ES2159346T3 (es) 2001-10-01
LT4349B (lt) 1998-05-25
AU5427996A (en) 1996-10-16
HK1013988A1 (en) 1999-09-17
IS4564A (is) 1997-09-22
BR9607790A (pt) 1998-07-07
DK1445259T3 (da) 2006-10-16
AT406771B (de) 2000-08-25
SE9703205L (sv) 1997-09-05
ZA962342B (en) 1997-09-22
IL117610A0 (en) 1996-07-23
LV12018B (en) 1998-09-20
EP1445259A1 (en) 2004-08-11
US5736541A (en) 1998-04-07
GB2313835A (en) 1997-12-10
MX9707183A (es) 1997-11-29
KR19980703188A (ko) 1998-10-15
ES2208220T3 (es) 2004-06-16
CN1179160A (zh) 1998-04-15
YU17796A (sh) 1999-03-04
GB9719819D0 (en) 1997-11-19
JPH11502535A (ja) 1999-03-02
EP1445259B1 (en) 2006-06-28
AU706471B2 (en) 1999-06-17
BG101900A (en) 1999-03-31
ATA902196A (de) 2000-01-15
CH690579A5 (de) 2000-10-31
CZ292688B6 (cs) 2003-11-12
CZ300097A3 (en) 1997-12-17
UA44765C2 (uk) 2002-03-15
LV12018A (lv) 1998-04-20
OA10510A (en) 2002-04-24
DE69630324D1 (de) 2003-11-13
DE69614426D1 (de) 2001-09-20
PL322501A1 (en) 1998-02-02
ATE331719T1 (de) 2006-07-15
TR199701017T1 (xx) 1998-01-21
PT1095941E (pt) 2004-02-27
HUP9802824A3 (en) 2000-01-28
ES2266719T3 (es) 2007-03-01
CN1065536C (zh) 2001-05-09
CA2214005A1 (en) 1996-10-03
DE69636313D1 (de) 2006-08-10
HU224989B1 (en) 2006-05-29
NO974365L (no) 1997-09-22
DE69614426T2 (de) 2002-05-23
EA199700262A1 (ru) 1998-02-26
SK121897A3 (en) 1998-03-04
LT97148A (en) 1998-01-26
LU90096B1 (fr) 1997-07-22
ATE204280T1 (de) 2001-09-15
SI1095941T1 (en) 2003-12-31
CO4650278A1 (es) 1998-09-03
EE9700232A (et) 1998-04-15
PT733635E (pt) 2001-12-28
CA2214005C (en) 2001-07-03
EP0733635B1 (en) 2001-08-16
DK1095941T3 (da) 2004-02-16
BG62619B1 (bg) 2000-03-31
YU49478B (sh) 2006-05-25
EP0733635A1 (en) 1996-09-25
GB2313835B (en) 1998-09-16
TW513432B (en) 2002-12-11
SI9620040A (sl) 1998-06-30
IL117610A (en) 2001-08-26
EG23659A (en) 2007-03-26
SI0733635T1 (en) 2002-06-30
KR100399688B1 (ko) 2004-02-18
AP828A (en) 2000-04-28
ZA962344B (en) 1997-09-22
DE69630324T2 (de) 2004-07-29
SE9703205D0 (sv) 1997-09-05
EA000149B1 (ru) 1998-10-29
DK108997A (da) 1997-11-12
SI9620040B (sl) 2002-02-28
MY114701A (en) 2002-12-31
DE69636313T2 (de) 2007-05-31
HUP9802824A2 (hu) 1999-06-28
ATE251627T1 (de) 2003-10-15
PE44897A1 (es) 1997-10-22
PL183723B1 (pl) 2002-07-31
IS1896B (is) 2003-10-20
AR002719A1 (es) 1998-04-29
EP1095941B1 (en) 2003-10-08
SK284143B6 (sk) 2004-10-05
TW442488B (en) 2001-06-23
DK0733635T3 (da) 2001-10-08
AP9701065A0 (en) 1997-10-31
AR010448A1 (es) 2000-06-28
RO118872B1 (ro) 2003-12-30
PA8353701A1 (es) 1998-09-18
PT1445259E (pt) 2006-10-31
DE19681286T1 (de) 1998-04-02
NO314663B1 (no) 2003-04-28
NZ306110A (en) 1998-09-24
SV1996000031A (es) 1998-03-27
NO974365D0 (no) 1997-09-22
WO1996030375A1 (en) 1996-10-03
EE03489B1 (et) 2001-08-15
EP1095941A1 (en) 2001-05-02

Similar Documents

Publication Publication Date Title
FI973750A0 (sv) Framställnig och kristallina former av 2-metyltienobensodiazepin
LV11983A (lv) Iekskigi lietojams 2-metil-tieno-benzodiazepina zalu preparats
EE03976B1 (et) Erütromütsiinid ja nende valmistamise meetod
FI941137A (sv) 2-debensoyl-2-acyltaxolderivat och förfaranden för framställning av dessa
BR9507179A (pt) Derivados de 3-aril-4-hidróxi-delta3-dihidrotiofena
BR9611130A (pt) Derivados de 3-aril-5-halógeno-pirona
KR970000228A (ko) S-에토돌락의 경구용 제제
IL118294A0 (en) Preparation of 4-aryl-piperidine derivatives
FI980246A0 (sv) F¦rfarande f¦r driften av en kokare och kokare
NO964395L (no) Fremstilling av puriner
EE03391B1 (et) Aminoetüületanoolamiini ja/või hüdroksüetüülpiperasiini saamise meetod
NZ300198A (en) Preparation of n-arylhydroxylamines and n-hetarylhydroxylamines
BR9306359A (pt) Azocorantes aplicação do azocorante e modificação cristalina
BR9607046A (pt) Derivados de 3-pirrolidiliden-2-ona-cefalosporinas
FI970828A (sv) Spirostanylglykocidkristaller
NO940171D0 (no) Fremgangsmaate for kontinuerlig fremstilling av dimetoksyetanal
KR960007598A (ko) 비스락톤계화합물 및 그 제조방법
NO991148L (no) Fremstilling av 1-butyl-4-piperidinyl-metylamin
FI953580A0 (sv) Framställning av acyklovir
NO974458D0 (no) Fremstilling av cis-4-O-beskyttede-2-cyklopentenolderivater
KR970026816U (ko) 쇼케이스의 도어착탈구조
KR960019764U (ko) 진주목걸이의 구조
FI974492A (sv) Ett moppmedel och ett förfarande för att fästa ett moppmedel
SV1993000010A (es) Preparacion de nuevas sulfonamidocarboxamidas
KR970041939U (ko) 부품의 방진체결구조